Suven Life Sciences to launch phase 3 clinical trial for Masupirdine
Suven Life Sciences is set to launch a phase 3 clinical trial for its 5-HT6 antagonist SUVN-502 (Masupirdine) for the treatment of agitation and aggression in Alzheimer’s type dementias. The Indian biopharma company expects to enroll patients from mid-September. Masupirdine is a selective, brain penetrant and orally active, chemical entity. Its late-stage study to be […]